Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Horwitz
    Horwitz
  2. Zelenetz
    Zelenetz
  3. Palomba
    Palomba
  4. Noy
    Noy
  5. Moskowitz
    Moskowitz
  6. Pulitzer
    Pulitzer
  7. Abdel-Wahab
    Abdel-Wahab
  8. Dogan
    Dogan
  9. Erinjeri
    Erinjeri
  10. Geller
    Geller

Groups

  1. Center for Hematologic Malignancies (56)
  2. Department of Medicine (56)
  3. Hematologic Malignancies, Division of (56)
  4. Lymphoma (56)
  5. Population Sciences Research Program (19)
  6. Executive Committee, Center for Hematologic Malignancies (13)
  7. Survivorship Research (8)
  8. Department of Pathology and Laboratory Medicine (7)
  9. Epidemiology and Biostatistics (5)
  10. GSK Faculty (5)
Search Within
  1. "Lymphoma"
Formats
  1. Journal Article (37)
  2. Meeting Abstract (13)
  3. Review (4)
  4. Correspondence (1)
  5. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (56)
  2. Department of Medicine (56)
  3. Hematologic Malignancies, Division of (56)
  4. Lymphoma (56)
  5. Population Sciences Research Program (19)
  6. Executive Committee, Center for Hematologic Malignancies (13)

More Groups

People
  1. Steven Horwitz (18)
  2. Anas Younes (11)
  3. Andrew Zelenetz (10)
  4. Maria Palomba (8)
  5. Ariela Noy (7)
  6. Matthew Matasar (7)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (3)
  4. 2022 (6)
  5. 2021 (6)
  6. 2020 (6)

More Years

Publications
  1. Lancet Oncology (16)
  2. The Lancet Haematology (13)
  3. Journal of Investigative Dermatology (7)
  4. Lancet (4)
  5. Experimental Hematology (3)
  6. Journal of Molecular Diagnostics (3)

More Publications

Results (56)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): A single-arm, open-label, phase 1, dose-escalation study
    Journal Article

    Iyer, S. P.; Sica, R. A.; Ho, P. J.; Prica, A.; Zain, J.; Foss, F. M.; Hu, B.; Beitinjaneh, A.; Weng, W. K.; Kim, Y. H.; more...
    Lancet Oncology (2025)

    Fulltext@MSK | Save
  • Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): A multicentre, open-label, single-arm, phase 2 study
    Journal Article

    Zinzani, P. L.; Izutsu, K.; Mehta-Shah, N.; Barta, S. K.; Ishitsuka, K.; Córdoba, R.; Kusumoto, S.; Bachy, E.; Cwynarski, K.; Gritti, G.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: A first-in-human, multicentre, open-label, single-arm, phase 1 study
    Journal Article

    Maruyama, D.; Jacobsen, E.; Porcu, P.; Allen, P.; Ishitsuka, K.; Kusumoto, S.; Narita, T.; Tobinai, K.; Foss, F.; Tsukasaki, K.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma
    Review

    Abramson, J. S.; Stuver, R.; Herrera, A.; Patterson, E.; Wen, Y. P.; Moskowitz, A.
    Critical Reviews in Oncology/Hematology (2024)

    Fulltext@MSK | Save
  • Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): Phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
    Journal Article

    Rubinstein, P. G.; Moore, P. C.; Bimali, M.; Lee, J. Y.; Rudek, M. A.; Chadburn, A.; Ratner, L.; Henry, D. H.; Cesarman, E.; DeMarco, C. E.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Validation of a high-sensitivity assay for detection of chimeric antigen receptor T-cell vectors using low-partition digital PCR technology
    Journal Article

    Arcila, M. E.; Patel, U.; Momeni-Boroujeni, A.; Yao, J.; Chan, R.; Chan, J.; Rijo, I.; Yu, W.; Chaves, N.; Patel, H.; more...
    Journal of Molecular Diagnostics (2023)

    Fulltext@MSK | Save
  • Giant cell myocarditis after mogamulizumab
    Meeting Abstract

    Marshall, D. P.; Sobol, I.; Horwitz, S.; Krishnan, U.; Abrams, J.; Zhang, C.; Mahmood, S. S.
    Journal of the American College of Cardiology (2023)

    Fulltext@MSK | Save
  • PI3K inhibitors in haematological malignancies
    Correspondence

    Matasar, M. J.; Hiemeyer, F.; Childs, B. H.; Zinzani, P. L.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Predictors of major hemorrhage after spleen core biopsy in cancer patients
    Journal Article

    Kunin, H.; Wijetunga, N. A.; Erinjeri, J. P.; Noy, A.; Deipolyi, A. R.
    Journal of Vascular and Interventional Radiology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study
    Journal Article

    Budde, L. E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save